Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | serine:threonine protein kinase MARK2 | 0.0672 | 1 | 1 |
Echinococcus multilocularis | serine:threonine protein kinase MARK2 | 0.0672 | 1 | 1 |
Echinococcus granulosus | serine:threonine protein kinase | 0.0384 | 0.251 | 0.2467 |
Schistosoma mansoni | serine/threonine protein kinase | 0.029 | 0.0057 | 0.0057 |
Echinococcus granulosus | serine:threonine protein kinase | 0.0384 | 0.251 | 0.2467 |
Echinococcus multilocularis | calcium activated potassium channel | 0.029 | 0.0057 | 0.0057 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0672 | 1 | 1 |
Schistosoma mansoni | serine/threonine kinase | 0.029 | 0.0057 | 0.0057 |
Loa Loa (eye worm) | hypothetical protein | 0.0384 | 0.251 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.029 | 0.0057 | 0.0057 |
Loa Loa (eye worm) | CAMK/CAMKL/MELK protein kinase | 0.029 | 0.0057 | 0.0226 |
Schistosoma mansoni | serine/threonine protein kinase | 0.029 | 0.0057 | 0.0057 |
Echinococcus multilocularis | serine:threonine protein kinase | 0.0384 | 0.251 | 0.251 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0384 | 0.251 | 1 |
Echinococcus multilocularis | serine:threonine protein kinase | 0.0384 | 0.251 | 0.251 |
Brugia malayi | Protein kinase domain containing protein | 0.029 | 0.0057 | 0.0226 |
Echinococcus granulosus | serine:threonine protein kinase MARK2 | 0.0672 | 1 | 1 |
Loa Loa (eye worm) | CAMK/CAMKL/MARK protein kinase | 0.0384 | 0.251 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0672 | 1 | 1 |
Brugia malayi | Protein kinase domain containing protein | 0.0384 | 0.251 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Dose/g (ADMET) | = 0.13 % | Biodistribution of compound in rat blood after 5 min of administration | ChEMBL. | 1956047 |
Dose/g (ADMET) | = 0.27 % | Biodistribution of compound in rat muscle after 5 min of administration | ChEMBL. | 1956047 |
Dose/g (ADMET) | = 0.66 % | Biodistribution of compound in rat lung after 5 min of administration | ChEMBL. | 1956047 |
Dose/g (ADMET) | = 1 % | Biodistribution of compound in rat heart after 5 min of administration | ChEMBL. | 1956047 |
Dose/g (ADMET) | = 1 % | Biodistribution of compound in rat liver after 5 min of administration | ChEMBL. | 1956047 |
Dose/g (ADMET) | = 9 % | Biodistribution of compound in rat kidney after 5 min of administration | ChEMBL. | 1956047 |
Plasma binding (ADMET) | = 6.6 % | The compound was tested for the plasma binding in rat | ChEMBL. | 1956047 |
Plasma binding (ADMET) | = 24 % | The compound was tested for the plasma binding in human | ChEMBL. | 1956047 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.